Tauxe R V, Puhr N D, Wells J G, Hargrett-Bean N, Blake P A
Division of Bacterial Diseases, Centers for Disease Control, Atlanta, GA 30333.
J Infect Dis. 1990 Nov;162(5):1107-11. doi: 10.1093/infdis/162.5.1107.
A nationwide sample of Shigella isolates was collected and tested for resistance to 12 antimicrobial agents to assess the prevalence and epidemiologic correlates of antimicrobial resistance in Shigella. Of the isolates, 32% were resistant to ampicillin, 7% to trimethoprim-sulfamethoxazole, and 0.4% to nalidixic acid. Fifty (20%) of 252 isolates were associated with foreign travel. The best predictor of clinically important resistance was a history of foreign travel: 20% of isolates from foreign travelers showed trimethoprim-sulfamethoxazole resistance, compared with only 4% of isolates from those without such a history. Quinolone resistance was not identified in travel-related isolates, and quinolones may be more appropriate for initial therapy of travel-related shigellosis than is trimethoprim-sulfamethoxazole.
收集了一份全国范围内的志贺氏菌分离株样本，并检测了其对12种抗菌药物的耐药性，以评估志贺氏菌中抗菌药物耐药性的流行情况及其流行病学相关因素。在这些分离株中，32%对氨苄青霉素耐药，7%对甲氧苄啶-磺胺甲恶唑耐药，0.4%对萘啶酸耐药。252株分离株中有50株（20%）与境外旅行有关。境外旅行史是临床上重要耐药性的最佳预测指标：来自境外旅行者的分离株中有20%显示对甲氧苄啶-磺胺甲恶唑耐药，而无此旅行史者的分离株中只有4%耐药。在与旅行相关的分离株中未发现喹诺酮耐药，与甲氧苄啶-磺胺甲恶唑相比，喹诺酮类药物可能更适合用于旅行相关志贺氏菌病的初始治疗。
